Literature DB >> 27641735

MicroRNA-1304 suppresses human non-small cell lung cancer cell growth in vitro by targeting heme oxygenase-1.

Cheng-Gang Li1,2, Meng-Fan Pu1,2, Chun-Zhu Li1,2, Man Gao1,2, Ming-Xia Liu1,2, Cun-Zhi Yu1,2, Hong Yan1,2, Chun Peng1,2, Yang Zhao1,2, Yu Li1,2, Ze-Long Ma1,2, Xin-Ming Qi1,2, Yi-Zheng Wang3, Ling-Ling Miao1,2, Jin Ren1,2.   

Abstract

Previous studies have shown that microRNA-1304 (miR-1304) is dysregulated in certain types of cancers, including non-small cell lung cancer (NSCLC), and might be involved in tumor survival and/or growth. In this study we investigated the direct target of miR-1304 and its function in NSCLC in vitro. Human lung adenocarcinoma cell lines (A549 and NCI-H1975) were studied. The cell proliferation and survival were investigated via cell counting, MTT and colony-formation assays. Cell apoptosis and cell cycle were examined using annexin V-PE/7-AAD and PI staining assays, respectively. The dual-luciferase reporter assay was used to verify post-transcriptional regulation of heme oxygenase-1 (HO-1) by miR-1304. CRISPR/Cas9 was used to deplete endogenous miR-1304. Overexpression of MiR-1304 significantly decreased the number and viability of NSCLC cells and colony formation, and induced cell apoptosis and G0/G1 phase cell cycle arrest. HO-1 was demonstrated to be a direct target of miR-1304 in NSCLC cells. Restoration of HO-1 expression by hemin (20 μmol/L) abolished the inhibition of miR-1304 on cell growth and rescued miR-1304-induced apoptosis in A549 cells. Suppression of endogenous miR-1304 with anti-1304 significantly increased HO-1 expression and promoted cell growth and survival in A549 cells. In 17 human NSCLC tissue samples, miR-1304 expression was significantly decreased, while HO-1 expression was significantly increased as compared to normal lung tissues. MicroRNA-1304 is a tumor suppressor and HO-1 is its direct target in NSCLC. The results suggest the potential for miR-1304 as a therapeutic target for NSCLC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27641735      PMCID: PMC5220548          DOI: 10.1038/aps.2016.92

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  30 in total

1.  Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells.

Authors:  Ryan D Morin; Michael D O'Connor; Malachi Griffith; Florian Kuchenbauer; Allen Delaney; Anna-Liisa Prabhu; Yongjun Zhao; Helen McDonald; Thomas Zeng; Martin Hirst; Connie J Eaves; Marco A Marra
Journal:  Genome Res       Date:  2008-02-19       Impact factor: 9.043

Review 2.  Getting to the root of miRNA-mediated gene silencing.

Authors:  Ana Eulalio; Eric Huntzinger; Elisa Izaurralde
Journal:  Cell       Date:  2008-01-11       Impact factor: 41.582

3.  Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.

Authors:  Murugabaskar Balan; Eduardo Mier y Teran; Ana Maria Waaga-Gasser; Martin Gasser; Toni K Choueiri; Gordon Freeman; Soumitro Pal
Journal:  J Biol Chem       Date:  2015-02-02       Impact factor: 5.157

Review 4.  The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets.

Authors:  Steven L Wood; Maria Pernemalm; Philip A Crosbie; Anthony D Whetton
Journal:  Cancer Treat Rev       Date:  2013-10-15       Impact factor: 12.111

5.  Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in thyroid cancer.

Authors:  Tao-Yeuan Wang; Chien-Liang Liu; Ming-Jen Chen; Jie-Jen Lee; Pou Chu Pun; Shih-Ping Cheng
Journal:  Histopathology       Date:  2014-11-25       Impact factor: 5.087

6.  A dual inhibition: microRNA-552 suppresses both transcription and translation of cytochrome P450 2E1.

Authors:  Lingling Miao; Hailan Yao; Chenggang Li; Mengfan Pu; Xuan Yao; Hui Yang; Xinming Qi; Jin Ren; Yizheng Wang
Journal:  Biochim Biophys Acta       Date:  2016-02-27

7.  Regulation of heme oxygenase-1 protein expression by miR-377 in combination with miR-217.

Authors:  Joan D Beckman; Chunseng Chen; Julia Nguyen; Venugopal Thayanithy; Subbaya Subramanian; Clifford J Steer; Gregory M Vercellotti
Journal:  J Biol Chem       Date:  2010-11-24       Impact factor: 5.157

8.  Signal peptide peptidase-mediated nuclear localization of heme oxygenase-1 promotes cancer cell proliferation and invasion independent of its enzymatic activity.

Authors:  F-F Hsu; C-T Yeh; Y-J Sun; M-T Chiang; W-M Lan; F-A Li; W-H Lee; L-Y Chau
Journal:  Oncogene       Date:  2014-06-16       Impact factor: 9.867

9.  The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer.

Authors:  Debashish Sahay; Raphael Leblanc; Thomas G P Grunewald; Srikant Ambatipudi; Johnny Ribeiro; Philippe Clézardin; Olivier Peyruchaud
Journal:  Oncotarget       Date:  2015-08-21

10.  Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells.

Authors:  Norahayu Othman; Lionel L A In; Jennifer A Harikrishna; Noor Hasima
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

View more
  19 in total

1.  Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A.

Authors:  Lei Zhang; Rong Hu; Yanyong Cheng; Xiaoyang Wu; Siwei Xi; Yu Sun; Hong Jiang
Journal:  Cell Prolif       Date:  2017-07-24       Impact factor: 6.831

2.  High expression of HO-1 predicts poor prognosis of ovarian cancer patients and promotes proliferation and aggressiveness of ovarian cancer cells.

Authors:  Z Zhao; Y Xu; J Lu; J Xue; P Liu
Journal:  Clin Transl Oncol       Date:  2017-08-14       Impact factor: 3.405

3.  Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update.

Authors:  Mayank Chaudhary; Pooja Sharma; Tapan Kumar Mukherjee
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

Review 4.  CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.

Authors:  Fatima Akram; Ikram Ul Haq; Sania Sahreen; Narmeen Nasir; Waqas Naseem; Memoona Imitaz; Amna Aqeel
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer.

Authors:  James Saller; Kun Jiang; Yin Xiong; Sean J Yoder; Kevin Neill; Jose M Pimiento; Luis Pena; F Scott Corbett; Anthony Magliocco; Domenico Coppola
Journal:  Dig Dis Sci       Date:  2021-03-13       Impact factor: 3.199

6.  MiR-1254 suppresses HO-1 expression through seed region-dependent silencing and non-seed interaction with TFAP2A transcript to attenuate NSCLC growth.

Authors:  Mengfan Pu; Chenggang Li; Xinming Qi; Jing Chen; Yizheng Wang; Lulu Gao; Lingling Miao; Jin Ren
Journal:  PLoS Genet       Date:  2017-07-27       Impact factor: 5.917

7.  A New Network-Based Strategy for Predicting the Potential miRNA-mRNA Interactions in Tumorigenesis.

Authors:  Jiwei Xue; Fanfan Xie; Junmei Xu; Yuan Liu; Yu Liang; Zhining Wen; Menglong Li
Journal:  Int J Genomics       Date:  2017-08-02       Impact factor: 2.326

8.  KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.

Authors:  Si-Si Li; Wei-Liang Jiang; Wen-Qin Xiao; Kai Li; Ye-Fei Zhang; Xing-Ya Guo; Yi-Qi Dai; Qiu-Yan Zhao; Ming-Jie Jiang; Zhan-Jun Lu; Rong Wan
Journal:  World J Gastrointest Oncol       Date:  2019-08-15

9.  Cigarette smoke and chewing tobacco alter expression of different sets of miRNAs in oral keratinocytes.

Authors:  Mohd Younis Bhat; Jayshree Advani; Pavithra Rajagopalan; Krishna Patel; Vishalakshi Nanjappa; Hitendra S Solanki; Arun H Patil; Firdous A Bhat; Premendu P Mathur; Bipin Nair; T S Keshava Prasad; Joseph A Califano; David Sidransky; Harsha Gowda; Aditi Chatterjee
Journal:  Sci Rep       Date:  2018-05-04       Impact factor: 4.379

10.  MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs.

Authors:  Jessica S Kurata; Ren-Jang Lin
Journal:  RNA       Date:  2018-05-02       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.